Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, First-in-Human, Open-Label, Multicenter Study of TORL-5-700 as a Monotherapy and in Combination for Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

NCT07439653 is registered in ClinicalTrials.gov with TORL Biotherapeutics, LLC as lead sponsor.

NCT NCT07439653
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07439653 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, First-in-Human, Open-Label, Multicenter Study of TORL-5-700 as a Monotherapy and in Combination for Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
Lead sponsor
TORL Biotherapeutics, LLC
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 31, 2026
Completion date
September 30, 2029
Enrollment
155 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

histologically confirmed relapsed or refractory b-cell non-hodgkin lymphoma